Revolutionizing mRNA Synthesis: TriLink & Alphazyme Launch CleanScribe™ RNA Polymerase

The collaboration between TriLink BioTechnologies® and Alphazyme has resulted in a groundbreaking innovation in mRNA synthesis: the launch of CleanScribe™ RNA Polymerase. This novel enzyme significantly reduces double-stranded RNA (dsRNA) formation during in vitro transcription (IVT), offering a solution to a longstanding challenge in mRNA therapeutics.


The CleanScribe RNA Polymerase reduces dsRNA by up to 85% compared to wild-type T7 RNA Polymerase, minimizing the risk of inflammatory responses in host cells. This improvement addresses a critical concern in mRNA therapeutics, as dsRNA can trigger unwanted immune reactions. By mitigating this issue, the CleanScribe enzyme enables the development of safer, more potent mRNA therapeutics.




The integration of CleanScribe RNA Polymerase into existing IVT protocols is straightforward, requiring minimal optimization. This simplicity allows researchers to readily adopt the enzyme, streamlining mRNA manufacturing processes. The robustness and reproducibility of the CleanScribe enzyme make it an ideal choice for various applications, including mRNA synthesis, self-amplifying RNA (saRNA) synthesis, radiolabeled RNA probe preparation, and RNA construct development for additional studies.




The launch of CleanScribe RNA Polymerase has significant implications for the competitive landscape of mRNA therapeutics and its potential market growth. As the demand for mRNA vaccines and therapeutics continues to rise, the ability to produce high-quality mRNA with reduced dsRNA content is crucial. The collaboration between TriLink and Alphazyme addresses this need, offering a competitive advantage to pharmaceutical companies and biotech startups.


In conclusion, the CleanScribe™ RNA Polymerase represents a major advancement in mRNA synthesis, enabling the development of safer and more effective mRNA therapeutics. Its compatibility with existing IVT protocols and significant reduction in dsRNA formation make it an attractive option for researchers and manufacturers alike. As the global mRNA market continues to grow, the impact of this collaboration on supply chain agility and market demand is expected to be substantial.